Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07070895 · ClinicalTrials.gov registry record · NA
Cough Management Wellness App for Refractory or Unexplained Chronic Cough
A NA study of Refractory Chronic Cough and Unexplained Chronic Cough, sponsored by Hyfe.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07070895: Recruiting NA study of Refractory Chronic Cough and Unexplained Chronic Cough, sponsored by Hyfe.
NCT07070895 is a NA study of Refractory Chronic Cough and Unexplained Chronic Cough that is actively recruiting participants, run by Hyfe. The registered enrollment target is 20 participants, below the 387-participant average among 5 other Refractory Chronic Cough trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07070895, a NA study of Refractory Chronic Cough and Unexplained Chronic Cough, is actively recruiting participants, sponsored by Hyfe.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this single-cohort clinical trial is to learn whether a smartphone-based Cough Management (CM) program can reduce cough frequency and burden in adults (21-80 years) who have refractory or unexplained chronic cough.  The main questions it aims to answer are: * Does four weeks of using the CM feature in the CoughPro app lower objective cough rate (coughs per hour) compared with each participant's one-week baseline?  * Does the program also lessen cough intensity (bout metrics) and improve patient-reported quality-of-life scores on the Leicester Cough Questionnaire and PGI-S? Participants will: * Wear a Hyfe CoughMonitor smartwatch continuously for 6 weeks (1-week baseline, 4-week intervention, 1-week follow-up), charging it nightly.  * Complete science-based in-app CM lessons based on behavioral cough-suppression therapy and practice the techniques during the 4-week intervention. * Fill out online questionnaires (LCQ and PGI-S) at baseline and at the end of Week 4. * Join a brief exit interview, then return the smartwatch and receive a compensation voucher.
Primary Outcome
Change in objective cough rate (coughs/hours) from baseline (week minus 1) to end of Week 4, measured by the CoughMonitor smartwatch.
Conditions Studied
Interventions
- BEHAVIORAL Cough Management
- DEVICE CoughMonitor Suite
Study Locations (1)
Delaware
- Hyfe Inc. - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-03-27 |
| Est. Completion | 2025-09 |
| Phase | NA |
What NCT07070895 shows while recruiting
NCT07070895 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 387-participant average among 5 other Refractory Chronic Cough trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Refractory Chronic Cough appearing as the primary indexed condition, and to 2 interventions - of which Cough Management is the first listed.
NCT07070895 reports a single indexed study location in Delaware.
Frequently Asked Questions
What is clinical trial NCT07070895 about?
NCT07070895 is a clinical study titled "Cough Management Wellness App for Refractory or Unexplained Chronic Cough". The goal of this single-cohort clinical trial is to learn whether a smartphone-based Cough Management (CM) program can reduce cough frequency and burden in adults (21-80 years) who have refractory or unexplained chronic cough.  The main questions it aims to answer are: * Does four weeks of using ...
What is the current status of trial NCT07070895?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-03-27. Estimated completion is 2025-09.
What conditions does trial NCT07070895 study?
This clinical trial studies the following conditions: Refractory Chronic Cough, Unexplained Chronic Cough, Cough Hypersensitivity.
What interventions are being tested in trial NCT07070895?
The interventions under investigation include: Cough Management (BEHAVIORAL), CoughMonitor Suite (DEVICE).
Who is sponsoring clinical trial NCT07070895?
This trial is sponsored by Hyfe, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07070895 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Chronic Cough
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
RECRUITING · Phase 3
-
Group Telehealth Behavioral Cough Suppression Therapy
RECRUITING · Early Phase 1
-
Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough
RECRUITING · Phase 2
-
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI